ライフサイエンスコーパス: ebolavirus

1 ebolavirus, Zaire ebolavirus, and Bundibugyo ebolavirus.

2 fective against viruses of the species Zaire ebolavirus.

3 igenically distinct species within the genus Ebolavirus.

4 ucleotide substitutions/site/year for Reston ebolavirus.

5 n catheters before being infected with Zaire ebolavirus.

6 own: Zaire, Sudan, Cote d'Ivoire, and Reston ebolavirus.

7 rom a lethal infection of guinea pig-adapted Ebolavirus.

8 ted from a lethal infection of mouse-adapted Ebolavirus.

9 e expressing a surface glycoprotein of Zaire Ebolavirus.

10 the surface structure and entry functions of ebolavirus.

11 viruses in the Filoviradae family, including ebolaviruses.

12 ed recombinant VSV encoding GP1,2 from these ebolaviruses.

13 irus (SUDV), as well as other wild-type (WT) ebolaviruses.

14 t affinities and specificities for different Ebolaviruses.

15 30% identical between Marburg virus and the ebolaviruses.

16 reporter cell line capable of detecting live ebolaviruses.

17 t occur in Sudan, Bundibugyo, and Tai Forest ebolaviruses.

18 tations may result in novel human pathogenic Ebolaviruses.

19 d protective efficacy against three virulent ebolaviruses.

20 izing antibodies against multiple species of ebolaviruses.

21 eston viruses from the four human pathogenic Ebolaviruses.

22 n the development of countermeasures against ebolaviruses.

23 Ebolavirus, a deadly hemorrhagic fever virus, was though

24 a phenotype similar to that of GP from Zaire ebolavirus, a highly pathogenic species, in terms of bot

25 GP from Reston ebolavirus, a nonpathogenic species in humans, showed a

26 Since VP24 is critical for Ebolavirus adaptation to novel hosts, and only a few SDP

27 are protected from disease on infection with ebolaviruses, although adapted versions of some of the v

28 There are five species of ebolavirus; among these, the Ebola (Zaire) and Sudan vir

29 ly lethal disease; wild-type ZEBOV and Sudan Ebolavirus and 4 different Marburg virus strains produce

30 frica, other ebolavirus species (e.g., Sudan ebolavirus and Bundibugyo ebolavirus) have also repeated

31 ibugyo virus (BDBV) is a member of the genus Ebolavirus and has caused outbreaks in the past but is r

32 Ebolavirus and Marburgvirus cause severe hemorrhagic fev

33 SV)-based filovirus vaccine vectors using wt Ebolavirus and Marburgvirus challenge strains.

34 Viruses in the Ebolavirus and Marburgvirus genera (family Filoviridae)

35 cellular receptor for the deadly filoviruses Ebolavirus and Marburgvirus has yet to be identified and

36 conserved epitope within the fusion loop of ebolavirus and marburgvirus species.

37 virus and differentiated between the genera Ebolavirus and Marburgvirus The amount of filovirus RNA

38 The investigational Ebolavirus and Marburgvirus WT GP DNA vaccines were safe

39 for replication of nonadapted wild-type (wt) Ebolavirus and Marburgvirus.

40 are required to prime the entry proteins of ebolavirus and other pathogenic viruses.

41 Here we report the development of pan-ebolavirus and pan-filovirus antibodies generated by rep

42 Here we report a set of pan-ebolavirus and pan-filovirus monoclonal antibodies (MAbs

43 re also important for rational design of pan-ebolavirus and pan-filovirus vaccines.

44 While there are five species of Ebolavirus and several strains of marburgvirus, the curr

45 ack only within the last 50 years for Reston ebolavirus and Zaire ebolavirus species and suggests tha

46 In addition to GP(1,2), ebolaviruses and cuevaviruses, but not marburgviruses, e

47 Ebolaviruses and marburgviruses belong to the family Fil

48 For almost 50 years, ebolaviruses and related filoviruses have been repeatedl

49 ecies of Ebolavirus (Zaire ebolavirus, Sudan ebolavirus, and Bundibugyo ebolavirus) associated with h

50 , Reston ebolavirus, Sudan ebolavirus, Zaire ebolavirus, and Bundibugyo ebolavirus.

51 Lloviu viruses, filoviruses (marburgviruses, ebolaviruses, and "cuevaviruses") cause severe viral hem

52 s are hosts of a range of viruses, including ebolaviruses, and many important human viral infections,

53 Multiple pan-ebolavirus antibodies were identified that react to the

54 provides a promising option for broad-acting ebolavirus antibody therapy and will accelerate the desi

55 In the Gulu case, ebolavirus antigen localized to malarial parasite pigmen

56 Ebolavirus antigen was seen in the syncytiotrophoblast a

57 Ebolaviruses are causative agents of lethal hemorrhagic

58 y Bray and by Lever et al suggesting that WT ebolaviruses are pathogenic in mice deficient for the ty

59 mutation may be unique to the species Zaire ebolavirus, as it does not occur in Sudan, Bundibugyo, a

60 as limited their use against other divergent ebolaviruses associated with human disease.

61 ebolavirus, Sudan ebolavirus, and Bundibugyo ebolavirus) associated with human disease, with no cross

62 Zaire ebolavirus (EBOV), Bundibugyo ebolavirus (BDBV), and Reston ebolavirus (RESTV) belong

63 Marburg virus (MARV) and the ebolaviruses belong to the family Filoviridae (the membe

64 ses and found two antibodies that showed pan-ebolavirus binding.

65 We examined the disease course of several WT ebolaviruses: Boneface (SUDV/Bon) and Gulu variants of S

66 , but not parent mAbs, neutralized all known ebolaviruses by coopting viral particles themselves for

67 Most ebolaviruses can cause severe disease in humans and othe

68 Ebolaviruses cause a severe hemorrhagic fever syndrome t

69 Ebolaviruses cause severe hemorrhagic fever.

70 more slowly progressive illness; and Reston Ebolavirus caused mild disease that was late in onset.

71 The recent West African outbreak of ebolavirus caused the deaths of more than 11,000 individ

72 Ebolavirus causes a severe hemorrhagic fever and is divi

73 Ebolavirus causes severe hemorrhagic fever, with case fa

74 Ebola virus (EBOV), formerly Zaire ebolavirus, causes a severe hemorrhagic disease in human

75 ebolavirus glycoproteins on marburgvirus and ebolavirus cell entry, using Fc-tagged recombinant prote

76 of nonhuman primates from lethal homologous Ebolavirus challenge.

77 OV), Zaire ebolavirus (ZEBOV), Cote d'Ivoire ebolavirus (CIEBOV), and Marburgvirus (MARV).

78 irus miRNA target genes, we suggest that two ebolavirus coding possible miRNAs may be silence and dow

79 Ebolaviruses constitute a public health threat, particul

80 Modern ebolavirus diagnostics rely primarily on quantitative re

81 o documented infection but immunoreactive to ebolavirus did not neutralize.

82 eral thousand people have been killed by the Ebolavirus disease (EVD) in West Africa, yet no current

83 Ebolavirus disease causes high mortality, and the curren

84 pathology and immune-mediated cell damage in ebolavirus disease often result in severe compromise of

85 Fc-tagged Delta-peptides from three ebolaviruses (Ebola virus, Sudan virus, and Tai Forest v

86 eplication-deficient, biologically contained Ebolavirus, EbolaDeltaVP30, which lacks the essential VP

87 Primary isolates of the filoviruses, i.e., ebolavirus (EBOV) and MARV, are not lethal to immunocomp

88 diagnostic test for rapid detection of Zaire ebolavirus (EBOV) and Sudan ebolavirus (SUDV).

89 Virologic investigation identified Zaire ebolavirus (EBOV) as the causative agent.

90 otective immunity against acute lethal Zaire ebolavirus (EBOV) challenge in macaques, but fail to pro

91 To determine whether Ebolavirus (EBOV) counters RNAi by encoding suppressors

92 Ebolavirus (EBOV) entry into cells requires proteolytic

93 on of host factors that are needed for Zaire Ebolavirus (EBOV) entry provides insights into the mecha

94 ors, such as Ad serotype 5 (Ad5), expressing Ebolavirus (EBOV) glycoprotein (GP), protect completely

95 es (MAbs; c2G4, c4G7, and c13C6) against the ebolavirus (EBOV) glycoprotein (GP), shows promise for c

96 atality rate (90%) similar to that for Zaire ebolavirus (EBOV) infection.

97 is, which has been shown to be important for ebolavirus (EBOV) infection.

98 Entry of ebolavirus (EBOV) into cells is mediated by its glycopro

99 Ebolavirus (EBOV) is a member of the filovirus family an

100 Transport of ebolavirus (EBOV) nucleocapsids from perinuclear viral i

101 Zaire ebolavirus (EBOV) VP35 is a double-stranded RNA (dsRNA)-

102 The ebolavirus (EBOV) VP35 protein binds to double-stranded

103 Viable Zaire ebolavirus (EBOV) was detected in aqueous humor 14 weeks

104 Ebolavirus (EBOV), an enveloped filamentous RNA virus ca

105 Ebolavirus (Ebov), an enveloped virus of the family Filo

106 Filoviruses, marburgvirus (MARV) and ebolavirus (EBOV), are causative agents of highly lethal

107 Zaire ebolavirus (EBOV), Bundibugyo ebolavirus (BDBV), and Res

108 he family Filoviridae contains three genera, Ebolavirus (EBOV), Marburg virus, and Cuevavirus.

109 5 inhibits multiple viruses, including Zaire ebolavirus (EBOV), Rift Valley fever virus (RVFV), Venez

110 A recombinant ebolavirus encoding L-mCherry instead of L was rescued a

111 evidence that in contrast to the new model, ebolavirus enters cells through endolysosomes that conta

112 ternate model was recently proposed in which ebolavirus enters through a later NPC1-negative endosome

113 Ca(2+) channel 2 (TPC2), a newly identified ebolavirus entry factor.

114 Additionally, the ebolavirus exploits the miRNAs to inhibit the NF-kB and

115 We determined structures of the Ebolavirus fusion loop and found residues critical for f

116 Here, using the genome-wide screening in ebolavirus genome sequences, we predicted four putative

117 We analyzed 196 Ebolavirus genomes and identified specificity determinin

118 Using Ebolavirus genomic and epidemiological data, we conducte

119 Hypothesizing that the closely related Ebolavirus genus may share the same Achilles' heel, we r

120 and Reston virus (RESTV) are members of the Ebolavirus genus which greatly differ in their pathogeni

121 24 proteins from EBOV and two members of the Ebolavirus genus, Bundibugyo virus (BDBV) and Reston vir

122 agent driven antigen sandwich assays for the Ebolavirus genus.

123 , indicating epitope conservation across the Ebolavirus genus.

124 of the receptor binding region (RBR) of the ebolavirus glycoprotein (GP) and infection by GP pseudov

125 an adenovirus type 5 vectors (rAd5) encoding ebolavirus glycoprotein (GP) generate protective immunit

126 ociated with a high antibody response to the Ebolavirus glycoprotein and the generation of an Ebolavi

127 Several monoclonal antibodies against the ebolavirus glycoprotein are currently in development as

128 ch of the MAbs in this cocktail binds to the ebolavirus glycoprotein as it is displayed-embedded in t

129 prime-boost vaccination regimen with a Zaire ebolavirus glycoprotein expression plasmid followed by i

130 and more complete picture of the accessible Ebolavirus glycoprotein landscape and a structural basis

131 ibes the generation of a panel of novel anti-ebolavirus glycoprotein monoclonal antibodies, including

132 cocktail of three MAbs directed against the ebolavirus glycoprotein, is a promising anti-ebolavirus

133 Here we report the generation of an ebolavirus glycoprotein-specific monoclonal antibody tha

134 lnerability in an internal fusion loop of an ebolavirus glycoprotein.

135 icular stomatitis virus expressing the Zaire ebolavirus glycoprotein.

136 icular stomatitis virus expressing the Zaire ebolavirus glycoprotein.

137 ernal fusion loop with the N terminus of the ebolavirus glycoproteins (GPs) and potently neutralizes

138 ted transmembrane-deleted and point-mutation Ebolavirus glycoproteins (GPs) in candidate vaccines.

139 omatitis virus (rVSV) pseudotypes expressing Ebolavirus glycoproteins (GPs) in place of the VSV G pro

140 We evaluated the effect of the secreted ebolavirus glycoproteins on marburgvirus and ebolavirus

141 s that exist in culture conditions and among ebolavirus glycoproteins.

142 d epitopes in this area neutralized all five ebolaviruses, guiding the development of a pan-ebolaviru

143 ainst the individual viral proteins of Sudan ebolavirus (Gulu) in human survivors was performed.

144 P lacking the transmembrane domain) of Sudan ebolavirus (Gulu) was used as well as a plaque reduction

145 The newly discovered Bundibugyo ebolavirus has been proposed as a 5th species.

146 Ebolaviruses have a surface glycoprotein (GP1,2) that is

147 31,100 cases since their discovery in 1976, ebolaviruses have caused approximately 13,000 deaths.

148 ecies (e.g., Sudan ebolavirus and Bundibugyo ebolavirus) have also repeatedly caused outbreaks in Cen

149 inguish Reston virus VP24 from VP24 of other Ebolaviruses, human pathogenic Reston viruses may emerge

150 2H7), might add to the understanding of anti-ebolavirus humoral immunity.IMPORTANCE This study descri

151 The ebolavirus immunotherapeutics field has replaced previou

152 olaviruses, guiding the development of a pan-ebolavirus immunotherapy.

153 ization was notified of an outbreak of Zaire ebolavirus in a remote area of Guinea.

154 for Bundibugyo, Sudan, and Zaire species of Ebolavirus in the domestic ferret, using wild-type nonad

155 sons who had occupational exposures to Zaire ebolavirus in West Africa received investigational agent

156 vided full protection against all pathogenic ebolaviruses in mice, guinea pigs, and ferrets.

157 red postexposure protection against multiple ebolaviruses in mice.

158 NP) appear to be major virulence factors for ebolaviruses in rodents, whereas VP40 appears to be the

159 e) species is the most lethal species of all ebolaviruses in terms of mortality rate and number of de

160 cap-specific mAbs that neutralized multiple ebolaviruses, including SUDV, and a cross-reactive mAb t

161 han being inert aggregates of nucleocapsids, ebolavirus inclusion bodies are in fact complex and dyna

162 erminal cleavage products of sGP secreted by ebolavirus-infected cells, inhibited entry of retrovirus

163 revealed a potential mechanism of miRNAs in ebolavirus infection and possible therapeutic targets fo

164 better understand humoral immunity following ebolavirus infection, a serological study of the humoral

165 the requirement for endosomal cathepsins for ebolavirus infection, identify the DC forms of these cat

166 okine storm" that is characteristic of fatal ebolavirus infection.

167 approved for the prevention or treatment of ebolavirus infection.

168 nockout mice, a susceptible animal model for Ebolavirus infection.

169 usion bodies are a characteristic feature of ebolavirus infections in cells.

170 zing antibodies are highly effective against ebolavirus infections, current experimental ebolavirus v

171 w its protective efficacy in mouse models of ebolavirus infections.

172 t are useful for clinical diagnosis of acute ebolavirus infections.

173 y-based treatment effective against multiple Ebolavirus infections.

174 NPC1) have been reported to promote entry of ebolaviruses into certain cellular systems.

175 Ebolavirus is a hemorrhagic fever virus associated with

176 Ebolavirus is a highly lethal pathogen, causing a severe

177 Ebolavirus is an enveloped virus causing severe hemorrha

178 The VP24 protein of Ebolavirus is an IFN antagonist, blocking type I IFN sig

179 ugh no licensed vaccine or treatment against ebolavirus is currently available, progress in preclinic

180 Zaire ebolavirus is the causative agent of the current outbrea

181 into five distinct species, of which Reston ebolavirus is uniquely nonpathogenic to humans.

182 Furthermore, VP24 from the ebolaviruses is immunosuppressive, while that of Marburg

183 broadly neutralizing antibodies (bNAbs) for ebolaviruses is possible but difficult, potentially due

184 these findings to the analysis of additional ebolavirus isolates and correctly predicted that the new

185 The Zaire Ebolavirus kit is based on the Filovirus Screen kit but

186 ch with a distinct function required for the ebolavirus life cycle.

187 ulties accessing the populations affected by ebolaviruses, little is also known about what constitute

188 These results provide a functional model for ebolavirus matrix assembly and the other roles of VP40 i

189 hat antibody-mediated protection against the Ebolaviruses may be achievable, but little is known abou

190 Host cell factors required for spread of ebolaviruses may serve as targets for antiviral interven

191 ics analysis and prediction of the potential ebolavirus miRNA target genes, we suggest that two ebola

192 dentified mAbs with exceptionally potent pan-ebolavirus neutralizing activity and protective efficacy

193 ged RBRs, whereas the Delta-peptide-Fc of an ebolavirus nonpathogenic for humans (Reston virus) and t

194 The C-terminal domain of Ebolavirus NP is a strong attractant for antibodies and

195 avirus glycoprotein and the generation of an Ebolavirus NP-specific CD8(+) T-cell response.

196 ntrations of 20-nt target sequences from the Ebolavirus nucleoprotein gene in a constant-temperature

197 la hemorrhagic fever (EHF) due to Bundibugyo ebolavirus occurred in Uganda from August to December 20

198 dividual rhesus macaques infected with Zaire ebolavirus over the entire disease course.

199 cess may be operative in cells important for ebolavirus pathogenesis (e.g., lymphocytes and macrophag

200 aim that lymphocytes, which are critical for ebolavirus pathogenesis, are refractory to infection bec

201 Growing understanding of ebolavirus pathogenetic mechanisms and important new cli

202 us inclusion bodies, we fused mCherry to the ebolavirus polymerase L, which is found in inclusion bod

203 Ebolaviruses pose significant public health problems due

204 The ongoing evolution of Ebolaviruses poses significant challenges to the develop

205 The ebolavirus protein VP35 adopts a unique bimodal configur

206 ity determining positions (SDPs) in all nine Ebolavirus proteins that distinguish Reston viruses from

207 novel functional insights in particular for Ebolavirus proteins VP40 and VP24.

208 Delta-peptides are functional components of ebolavirus proteomes.

209 The emergence of Reston ebolavirus (REBOV) in domestic swine in the Philippines

210 ome, have now been discovered to host Reston ebolavirus (REBOV).

211 rorism, the development of a vaccine against ebolavirus remains a top priority.

212 cacy, rodent models have been widely used in ebolavirus research because of their convenience.

213 A major obstacle in ebolavirus research is the lack of a small-animal model

214 Ebola virus (EBOV) (genera Marburgvirus and Ebolavirus, respectively).

215 us species: Marburg marburgvirus, Tai Forest ebolavirus, Reston ebolavirus, Sudan ebolavirus, Zaire e

216 V), Bundibugyo ebolavirus (BDBV), and Reston ebolavirus (RESTV) belong to the same genus but exhibit

217 th Sudan virus (SUDV), a member of the genus Ebolavirus, result in a severe hemorrhagic fever with a

218 (RT-PCR) kit and the derived RealStar Zaire Ebolavirus RT-PCR kit were validated using in vitro tran

219 e expressing a surface glycoprotein of Zaire Ebolavirus (rVSV-ZEBOV) is a promising Ebola vaccine can

220 tic sdAb library which was mined for an anti-Ebolavirus sdAb which was immediately immunoassay ready,

221 treated in parallel with heterologous Sudan ebolavirus (SEBOV) convalescent macaque sera, and 2 anim

222 (MARV), Zaire ebolavirus (ZEBOV), and Sudan ebolavirus (SEBOV), cause severe and often fatal hemorrh

223 f protecting nonhuman primates against Sudan ebolavirus (SEBOV), Zaire ebolavirus (ZEBOV), Cote d'Ivo

224 ound in any Sudan, Bundibugyo, or Tai Forest ebolavirus sequences.

225 in Central and, recently, West Africa, other ebolavirus species (e.g., Sudan ebolavirus and Bundibugy

226 he differences in pathogenicity reported for ebolavirus species and suggest that proinflammatory path

227 ast 50 years for Reston ebolavirus and Zaire ebolavirus species and suggests that viruses within thes

228 imental and clinical samples, independent of ebolavirus species and variant.

229 bodies binding to the core GP1 region of all ebolavirus species and with lower affinity to MARV GP cr

230 Different ebolavirus species are associated with widely varying pa

231 s determining the pathogenicity of different ebolavirus species are not yet known.

232 orrectly predicted that the newly identified ebolavirus species Bundibugyo, containing D47 and I584,

233 iruses within Marburg marburgvirus and Sudan ebolavirus species can be traced back further and share

234 Reston virus, the only non-human pathogenic Ebolavirus species circulates in pigs in Asia, this rais

235 ntry of representative isolates of all known ebolavirus species in vitro and show its protective effi

236 ve antibodies that bind the GPs of all known Ebolavirus species will give us important insight into t

237 react between the glycoproteins of different ebolavirus species, and the mechanism of these monoclona

238 heir breadth of reactivity against different ebolavirus species, predict viral evasion against these

239 tection against viruses belonging to diverse Ebolavirus species, such as Ebola virus (EBOV), Sudan vi

240 to the antigenic differences among the five ebolavirus species, the current therapeutic monoclonal a

241 the basis of sequence homology between the 5 Ebolavirus species, we hypothesize that conserved epitop

242 y and protection is observed between these 5 Ebolavirus species, which complicates vaccine developmen

243 lized both SUDV and EBOV, the most divergent ebolavirus species.

244 LISA as cross-reacting with the GPs of all 5 Ebolavirus species.

245 ies with broad cross-reactivity to all known ebolavirus species.

246 hogenicity between Reston and the other four ebolavirus species.

247 assay platforms for detecting VP40 and other ebolavirus-specific immunoglobulins.

248 study investigates the viability of 2 Zaire ebolavirus strains within aerosols at 22 degrees C and 8

249 utbreak caused by other members of the genus Ebolavirus, such as Sudan virus (SUDV), is not readily a

250 strongly dependent on cathepsin B, while the ebolaviruses Sudan and Reston and Marburg virus are not.

251 ensitivity to 3 species of Ebolavirus (Zaire ebolavirus, Sudan ebolavirus, and Bundibugyo ebolavirus)

252 marburgvirus, Tai Forest ebolavirus, Reston ebolavirus, Sudan ebolavirus, Zaire ebolavirus, and Bund

253 udinal serum samples from survivors of Sudan ebolavirus (SUDV) infection, studied over years, were ex

254 ct against other Ebola species such as Sudan ebolavirus (SUDV).

255 tection of Zaire ebolavirus (EBOV) and Sudan ebolavirus (SUDV).

256 n capacity of the humoral immune response in ebolavirus survivors.

257 t respiratory syndrome coronavirus and Zaire Ebolavirus templates into glucose signals, with a sensit

258 Reston viruses are the only Ebolaviruses that are not pathogenic in humans.

259 ebolavirus glycoprotein, is a promising anti-ebolavirus therapeutic.

260 indings should inform future developments of ebolavirus therapeutics.

261 ade in developing therapeutics against Zaire ebolavirus, these therapies do not protect against other

262 nucleotide substitutions/site/year for Sudan ebolavirus to 8.21 x 10(-4) nucleotide substitutions/sit

263 However, the factors used by ebolaviruses to invade macrophages, major viral targets,

264 fection may be a mechanism of transplacental ebolavirus transmission.

265 binant chimpanzee adenovirus type 3-vectored ebolavirus vaccine (cAd3-EBO), encoding the glycoprotein

266 ve important implications for developing pan-ebolavirus vaccine and immunotherapeutic cocktails.

267 Here, we will review ebolavirus vaccine candidates and considerations for the

268 comolar affinity, suggesting that engineered ebolavirus vaccines could trigger rare bNAb precursors m

269 ebolavirus infections, current experimental ebolavirus vaccines primarily elicit species-specific an

270 t a high titer of Ebola virus (species Zaire ebolavirus) variant Makona in spiked human serum samples

271 Here, we demonstrate that ebolavirus VP35 also coats the dsRNA backbone in solutio

272 This work illustrates how ebolavirus VP35 could mask key recognition sites of mole

273 Crystal structures of ebolavirus VP35 show that it caps dsRNA ends to prevent

274 ctures of the dsRNA-binding domain of Reston ebolavirus VP35.

275 Systematic investigation of ebolavirus whole genomes during the 2014 outbreak may sh

276 nic for humans (Reston virus) and that of an ebolavirus with lower lethality for humans (Bundibugyo v

277 in this trial encode wild-type (WT) GP from Ebolavirus Zaire and Sudan species and the Marburgvirus

278 irus Zaire-1995, the single known isolate of ebolavirus Zaire that lacks D47, is not.

279 and I584, is cathepsin B dependent and that ebolavirus Zaire-1995, the single known isolate of ebola

280 omal cysteine proteases are host factors for ebolavirus Zaire.

281 coma/leukosis virus (ASLV) and the filovirus ebolavirus Zaire.

282 nockout-derived cell lines, we show that the ebolaviruses Zaire and Cote d'Ivoire are strongly depend

283 RDT demonstrated sensitivity to 3 species of Ebolavirus (Zaire ebolavirus, Sudan ebolavirus, and Bund

284 Forest ebolavirus, Reston ebolavirus, Sudan ebolavirus, Zaire ebolavirus, and Bundibugyo ebolavirus.

285 stomatitis virus (VSV) expressing the Zaire ebolavirus (ZEBOV) and Andes virus (ANDV) glycoproteins

286 , replication and spread of infectious Zaire ebolavirus (ZEBOV) and Lake Victoria marburgvirus (MARV)

287 use diagnostic assays for detection of Zaire ebolavirus (ZEBOV) are urgently needed.

288 A mouse-adapted Zaire ebolavirus (ZEBOV) caused rapidly lethal disease; wild-t

289 ine-mediated protection against lethal Zaire ebolavirus (ZEBOV) challenge.

290 Zaire Ebolavirus (ZEBOV) continues to pose a significant threa

291 amily member, is necessary for optimal Zaire ebolavirus (ZEBOV) glycoprotein (GP)-dependent entry int

292 irus (rVSV)-based vaccine expressing a Zaire ebolavirus (ZEBOV) glycoprotein was selected for rapid s

293 oclonal antibodies (MAbs) specific for Zaire ebolavirus (ZEBOV) have been successfully used in passiv

294 to treat patients during outbreaks of Zaire ebolavirus (ZEBOV) infection in 1976 and 1995, with inco

295 guinea pigs could be protected against Zaire ebolavirus (ZEBOV) infection only when immunized with a

296 The most recent Zaire Ebolavirus (ZEBOV) outbreak was the largest and most wid

297 e encoding the surface glycoprotein of Zaire ebolavirus (ZEBOV) to 60 healthy adult volunteers in Oxf

298 oviruses, Marburg marburgvirus (MARV), Zaire ebolavirus (ZEBOV), and Sudan ebolavirus (SEBOV), cause

299 e members of the EBOV genus, including Zaire ebolavirus (ZEBOV), can cause lethal haemorrhagic fever

300 ates against Sudan ebolavirus (SEBOV), Zaire ebolavirus (ZEBOV), Cote d'Ivoire ebolavirus (CIEBOV), a